Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Combined effects of adeno-associated virus vector and a herpes simplex virus mutant as neoplastic therapy
Autore:
Kasuya, H; Mizuno, M; Yoshida, J; Nishiyama, Y; Nomoto, S; Nakao, A;
Indirizzi:
Nagoya Univ, Sch Med, Dept Neurosurg, Showa Ku, Nagoya, Aichi 4668550, Japan Nagoya Univ Nagoya Aichi Japan 4668550 a Ku, Nagoya, Aichi 4668550, Japan Nagoya Univ, Sch Med, Dept Surg 2, Nagoya, Aichi 466, Japan Nagoya Univ Nagoya Aichi Japan 466 Dept Surg 2, Nagoya, Aichi 466, Japan Nagoya Univ, Sch Med, Dis Mechanism & Control Res Inst, Virol Lab, Nagoya,Aichi 466, Japan Nagoya Univ Nagoya Aichi Japan 466 st, Virol Lab, Nagoya,Aichi 466, Japan
Titolo Testata:
JOURNAL OF SURGICAL ONCOLOGY
fascicolo: 3, volume: 74, anno: 2000,
pagine: 214 - 218
SICI:
0022-4790(200007)74:3<214:CEOAVV>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
RECOMBINANT ADENOASSOCIATED VIRUS; THYMIDINE KINASE GENE; LONG-TERM SURVIVAL; RIBONUCLEOTIDE REDUCTASE; DNA-SYNTHESIS; GANCICLOVIR; REPLICATION; DELIVERY; GLIOMAS; TUMORS;
Keywords:
AAV vector; ICP6 Delta gene therapy; pancreatic cancer;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Yoshida, J Nagoya Univ, Sch Med, Dept Neurosurg, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan Nagoya Univ 65 Tsurumai Cho Nagoya Aichi Japan 4668550 0, Japan
Citazione:
H. Kasuya et al., "Combined effects of adeno-associated virus vector and a herpes simplex virus mutant as neoplastic therapy", J SURG ONC, 74(3), 2000, pp. 214-218

Abstract

Background and Objectives: Although surgical therapy for pancreatic cancerhas not been successful, new gene therapies, such as adenoassociated virus(AAV) vectors hold promise for treating cancer. However, expression of AAVvectors alone is insufficient for adequate effects in vivo for cancer therapy. We describe a novel therapy using the combined herpes simplex virus-ICP6 deletion mutant (ICP6 Delta) and AAV vector. Methods: We investigated ICP6 Delta and AAV regarding kinetics and dose-response relationships of LacZ expression in vitro. We studied the expressionof LacZ in vivo using subcutaneous pancreatic cancer tumors (SW1990) in nude mice. Results: In vitro, ICP6 Delta enhanced the expression of AAV; 24 hr following inoculation there was more expression with AAV plus ICP6 Delta than with AAV plus KOS, and a multiplicity of infection (MOI) of 0.5 was the optimal titer of ICP6 Delta to support maximal expression of AAV. In vivo, there was much higher expression of LacZ in mice injected with AAV-LacZ plus ICP6Delta. than with AAV-LacZ alone. Conclusions: ICP6 Delta enhances expression of AAV-vector in vitro and in vivo. These results suggested that combined therapy have potential for human cancer. J. Surg. Oncol. 2000:74:214-218. (C) 2000 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/06/20 alle ore 02:20:21